drugset / Trial / NCT02276508
Open Label Trial of Nissle 1917
NaSingle-groupOpen-label
Summary
Nissle 1917 is an E. coli based probiotic used in the Europe for close to 100 years to treat gastrointestinal disorders and infections. The investigators will assess the safety and tolerability of this medication in Americans in a Phase 1 trial.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-12
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nissle 1917 | Other / unclassified | 200 mg | Oral |